P
86.15
0.36 (0.42%)
| Previous Close | 85.79 |
| Open | 86.58 |
| Volume | 400,862 |
| Avg. Volume (3M) | 1,184,834 |
| Market Cap | 5,385,724,416 |
| Price / Earnings (TTM) | 130.53 |
| Price / Earnings (Forward) | 26.39 |
| Price / Sales | 29.25 |
| Price / Book | 9.24 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | 27.04% |
| Operating Margin (TTM) | -68.18% |
| Diluted EPS (TTM) | 0.780 |
| Quarterly Revenue Growth (YOY) | -88.90% |
| Quarterly Earnings Growth (YOY) | 381.70% |
| Total Debt/Equity (MRQ) | 1.65% |
| Current Ratio (MRQ) | 17.25 |
| Operating Cash Flow (TTM) | 336.94 M |
| Levered Free Cash Flow (TTM) | 327.76 M |
| Return on Assets (TTM) | 2.48% |
| Return on Equity (TTM) | 8.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Protagonist Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
1.6
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 2.0 |
| Average | 1.63 |
|
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.10% |
| % Held by Institutions | 108.49% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Farallon Capital Management Llc | 30 Sep 2025 | 6,196,006 |
| Rtw Investments, Lp | 30 Sep 2025 | 5,756,277 |
| Johnson & Johnson | 30 Sep 2025 | 2,449,183 |
| Deep Track Capital, Lp | 30 Sep 2025 | 1,715,691 |
| Woodline Partners Lp | 30 Sep 2025 | 1,438,247 |
| Price T Rowe Associates Inc /Md/ | 30 Sep 2025 | 1,220,436 |
| Driehaus Capital Management Llc | 30 Sep 2025 | 1,139,854 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 115.00 (Citigroup, 33.49%) | Buy |
| Median | 87.00 (0.99%) | |
| Low | 80.00 (HC Wainwright & Co., -7.14%) | Buy |
| Average | 92.75 (7.66%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 79.94 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 17 Dec 2025 | 108.00 (25.36%) | Buy | 89.34 |
| 07 Nov 2025 | 88.00 (2.15%) | Buy | 79.54 | |
| Citigroup | 08 Dec 2025 | 115.00 (33.49%) | Buy | 90.25 |
| 10 Nov 2025 | 98.00 (13.76%) | Buy | 83.23 | |
| Citizens | 07 Nov 2025 | 102.00 (18.40%) | Buy | 79.54 |
| JP Morgan | 07 Nov 2025 | 81.00 (-5.98%) | Buy | 79.54 |
| BTIG | 28 Oct 2025 | 82.00 (-4.82%) | Buy | 78.51 |
| Truist Securities | 28 Oct 2025 | 88.00 (2.15%) | Buy | 78.51 |
| Wedbush | 28 Oct 2025 | 86.00 (-0.17%) | Buy | 78.51 |
| HC Wainwright & Co. | 08 Oct 2025 | 80.00 (-7.14%) | Buy | 65.30 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |